Sitemap
Sitemap
Careers
News
- 30 Technology enters into a strategic Licencing Agreement to develop new treatments for multi-drug resistant tuberculosis
- 30 Technology launches a critical clinical trial of RESP301 in cystic fibrosis patients with serious lung infections
- Thirty Respiratory receives approval for multicentre post-exposure clinical trial of RESP301 to prevent transmission of COVID-19 in the community
- 30 Technology gets the go-ahead for multicentre clinical trial (CORVIS) in the UK of RESP301 in patients with COPD and viral exacerbations, including COVID-19
- 30 Technology announces first patients enrolled in UK clinical trial (NOCoV2) for the treatment of COVID-19
- Thirty Respiratory gets Regulatory Approval to start international, open-label, randomised, multi-centre Phase 2/3 trial of RESP301 in patients hospitalised with COVID-19
30 TECHNOLOGY Therapeutic Nitric Oxide